US 12,150,939 B2
Therapeutic drug for ectopic ossification having mechanism to inhibit PAR1
Takumi Era, Kumamoto (JP); and Takayuki Kiboku, Kumamoto (JP)
Assigned to NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, Kumamoto (JP)
Filed by NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, Kumamoto (JP)
Filed on Nov. 30, 2020, as Appl. No. 17/106,565.
Application 17/106,565 is a division of application No. 15/776,152, abandoned, previously published as PCT/JP2016/084101, filed on Nov. 17, 2016.
Claims priority of application No. 2015-228232 (JP), filed on Nov. 20, 2015.
Prior Publication US 2021/0161872 A1, Jun. 3, 2021
Int. Cl. A61K 31/443 (2006.01); A61P 19/08 (2006.01)
CPC A61K 31/443 (2013.01) [A61P 19/08 (2018.01)] 8 Claims
OG exemplary drawing
 
1. A method for treating or suppressing ectopic ossification, comprising treating or suppressing ectopic ossification by administering a Protease-Activated Receptor-1 (PAR1) inhibitor to a subject having a disease involving the ectopic ossification which occurs by an inflammation due to an injury.